When a Settlement Agreement's Words Cost $16 Million: Lessons from the Lexapro Patent Dispute

When a Settlement Agreement's Words Cost $16 Million: Lessons from the Lexapro Patent Dispute

How do you value the words in a patent settlement agreement? In the long-running Lexapro litigation, that question had a $16 million answer — and the Full Federal Court of Australia ultimately concluded that the first instance judge got it wrong. Sandoz Pty Ltd v H Lundbeck A/S [2020] FCAFC 133 is a landmark decision that goes to the heart of commercial contract construction, patent term extensions, and the high stakes of pharmaceutical patent litigation in Australia.

Background: The Lexapro Patent Saga

Escitalopram — sold under the brand name Lexapro — is one of the world's best-selling antidepressants. H Lundbeck A/S, the Danish pharmaceutical company, held Australian patents covering escitalopram. The original 20-year patent term was due to expire in June 2009. Lundbeck had obtained a patent term extension in 2004 (pharmaceutical patents can be extended by up to five years in Australia under the Patents Act 1990 (Cth)), but that extension was ultimately held invalid through separate litigation.

In 2007, Lundbeck and Sandoz — a generic pharmaceutical manufacturer — were locked in patent litigation. They settled. The settlement gave Sandoz what was described as an "early-entry licence" to sell generic escitalopram commencing two weeks before the original patent expiry date of June 2009. What nobody fully anticipated at the time was the tortuous subsequent history: Lundbeck would eventually succeed in obtaining a new, valid five-year patent term extension in June 2014, backdated to cover the period from June 2009 through to December 2012.

That meant the patent was, retroactively, in force during a period when Sandoz had already been selling generic escitalopram — the very period that Sandoz believed was covered by its 2007 licence. The question that made its way to the Full Federal Court (and ultimately to the High Court for the third time in this litigation) was deceptively simple: did the early-entry licence continue to operate during the extended term?

The First Instance Decision and Its $16 Million Finding

At first instance, Justice Jagot found in favour of Lundbeck. Her Honour held that the early-entry licence, properly construed, commenced in May 2009 (two weeks before original expiry) and ceased to operate when the original patent expired in June 2009. The licence could not, in Justice Jagot's view, extend to cover a patent term extension that was not in contemplation when the settlement was struck in 2007.

That construction meant Sandoz had no licence covering its generic sales during the extended term — and was therefore liable for infringement. Damages were assessed at over AUD $16 million, making it one of the most significant pharmaceutical patent damages awards in Australian history at that time.

The Full Federal Court's Reversal

The Full Federal Court — comprising Justices Greenwood, Nicholas and Burley — disagreed with that construction. Their Honours applied the well-established principles of objective commercial construction: the proper meaning of a commercial contract is determined not by the subjective intentions of the parties, but by what a reasonable businessperson in the parties' position would have understood the words to mean, having regard to the surrounding circumstances known to both parties at the time of contracting.

Several features of the 2007 settlement agreement pointed toward the licence continuing during any extended term. The settlement was intended to resolve all patent litigation between the parties relating to escitalopram. A construction that caused Sandoz to be a patent infringer the moment it exercised the rights it had just been granted — because of a retroactive extension that nobody controlled — would produce a commercially absurd result. The Full Court was not prepared to attribute such an intention to sophisticated commercial parties negotiating at arm's length.

Applying these principles, the Full Court held that the early-entry licence continued to operate during the extended term of the patent. Sandoz was not liable for patent infringement. The $16 million damages award was set aside.

Key Legal Principles

Objective Commercial Construction

Australian courts interpret commercial contracts by asking what the words would convey to a reasonable businessperson with knowledge of the background facts known to the parties. Subjective intentions are irrelevant. The court looks at the document as a whole, in its commercial context, to give it a meaning that makes commercial sense.

Avoiding Commercially Absurd Results

Courts will strain against a construction that produces a result no reasonable businessperson would have intended. Where two constructions are available, the one that gives commercial effect to the agreement — rather than one that creates immediate absurdity — will generally prevail.

Patent Term Extensions and Uncertainty

This case illustrates that patent term extensions in Australia can have retroactive effect in complex litigation scenarios. When settling pharmaceutical patent disputes, parties must carefully consider what happens if the patent's term is later varied — whether extended or curtailed — after the settlement deed is executed.

Strategic Takeaways for Businesses

• Draft settlement agreements for future uncertainty. When settling IP litigation, consider expressly addressing what happens if the underlying IP right is subsequently varied, extended, or invalidated. Silence on this point creates ambiguity that can cost millions.

• Patent term extensions are litigable events. In the pharmaceutical sector particularly, a patent term extension can dramatically change the competitive landscape — and trigger further litigation — years after the original patent was thought to have expired.

• Objective construction cuts both ways. A well-drafted settlement agreement gives certainty. A poorly drafted one means a court will determine what "reasonable businesspeople" intended — and that finding may surprise you.

• Budget for appeals in high-stakes matters. This dispute reached the Full Federal Court and the High Court (multiple times). At these stakes, assume that every major finding will be tested on appeal.

• Seek specialist IP advice before entering settlement agreements. The interaction between settlement terms, patent term extensions, and damages exposure is complex. The cost of careful drafting upfront is a fraction of the litigation risk.

Conclusion

Sandoz v Lundbeck [2020] is a reminder that a patent dispute does not end when the parties settle — especially in an industry where patent terms can be extended through litigation years after the original dispute was resolved. The $16 million question was ultimately answered by what reasonable businesspeople would have intended. The Full Court's answer vindicated Sandoz, but the years of litigation preceding that vindication were costly for everyone.

Whether you are a pharmaceutical innovator, a generic manufacturer, or any business navigating IP licensing and settlement agreements, the lessons from this case are clear: precise drafting saves money, and specialist IP counsel is an investment, not a cost.

If your business is facing patent disputes, licensing negotiations, or settlement agreements involving Australian IP rights, contact Stellar IP Law for expert, practical advice.